Autolus Therapeutics Ltd (NASDAQ:AUTL) — Market Cap & Net Worth
Market Cap & Net Worth: Autolus Therapeutics Ltd (AUTL)
Autolus Therapeutics Ltd (NASDAQ:AUTL) has a market capitalization of $396.55 Million ($396.55 Million) as of August 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #13281 globally and #3222 in its home market, demonstrating a -1.97% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Autolus Therapeutics Ltd's stock price $1.49 by its total outstanding shares 266143286 (266.14 Million). Review Autolus Therapeutics Ltd (AUTL) total liabilities to assess the company's total debt and financial obligations.
Autolus Therapeutics Ltd Market Cap History: 2018 to 2026
Autolus Therapeutics Ltd's market capitalization history from 2018 to 2026. Data shows change from $8.74 Billion to $396.55 Million (-29.36% CAGR).
Index Memberships
Autolus Therapeutics Ltd is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.02% | #359 of 976 |
|
NASDAQ Composite
IXIC
|
$40.26 Trillion | 0.00% | #1307 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.72 Trillion | 0.02% | #195 of 263 |
Weight: Autolus Therapeutics Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Autolus Therapeutics Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Autolus Therapeutics Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
7.01x
Autolus Therapeutics Ltd's market cap is 7.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $8.74 Billion | $1.05 Million | -$31.11 Million | 8361.03x | N/A |
| 2018 | $8.74 Billion | $1.05 Million | -$31.11 Million | 8361.03x | N/A |
| 2019 | $3.51 Billion | $2.91 Million | -$123.85 Million | 1208.08x | N/A |
| 2020 | $2.38 Billion | $1.72 Million | -$142.09 Million | 1387.36x | N/A |
| 2021 | $1.38 Billion | $1.51 Million | -$142.10 Million | 916.58x | N/A |
| 2022 | $505.67 Million | $6.19 Million | -$148.84 Million | 81.64x | N/A |
| 2023 | $1.71 Billion | $1.70 Million | -$208.38 Million | 1009.40x | N/A |
| 2024 | $625.44 Million | $10.12 Million | -$220.66 Million | 61.80x | N/A |
| 2025 | $529.63 Million | $75.56 Million | -$288.20 Million | 7.01x | N/A |
Competitor Companies of AUTL by Market Capitalization
Companies near Autolus Therapeutics Ltd in the global market cap rankings as of August 1, 2026.
Key companies related to Autolus Therapeutics Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
Autolus Therapeutics Ltd Historical Marketcap From 2018 to 2026
Between 2018 and today, Autolus Therapeutics Ltd's market cap moved from $8.74 Billion to $ 396.55 Million, with a yearly change of -29.36%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $396.55 Million | -25.13% |
| 2025 | $529.63 Million | -15.32% |
| 2024 | $625.44 Million | -63.51% |
| 2023 | $1.71 Billion | +238.95% |
| 2022 | $505.67 Million | -63.39% |
| 2021 | $1.38 Billion | -41.95% |
| 2020 | $2.38 Billion | -32.27% |
| 2019 | $3.51 Billion | -59.81% |
| 2018 | $8.74 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 1st, 2026 the market cap of Autolus Therapeutics Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $396.55 Million USD |
| MoneyControl | $396.55 Million USD |
| MarketWatch | $396.55 Million USD |
| marketcap.company | $396.55 Million USD |
| Reuters | $396.55 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Autolus Therapeutics Ltd
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-c… Read more